GlobeNewswire - Industry News on Health Care http://www.yebxqs.cn/RssFeed/industry/4000-Health%20Care/feedTitle/GlobeNewswire%20-%20Industry%20News%20on%20Health%20Care Contains the last 20 releases newsdesk@globenewswire.com (NewsDesk) Wed, 24 Feb 2021 17:15:00 GMT webmaster@globenewswire.com (Webmaster) http://www.yebxqs.cn/news-release/2021/02/24/2181731/0/en/BBS-Bioactive-Bone-Substitutes-Plc-Financial-Statements-Review-1-1-31-12-2020-unaudited.html http://www.yebxqs.cn/news-release/2021/02/24/2181731/0/en/BBS-Bioactive-Bone-Substitutes-Plc-Financial-Statements-Review-1-1-31-12-2020-unaudited.html Helsinki:BONEH Stockholm:BONEH FI4000260583 8877 BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2020 (unaudited) Financial statement release on 24 February 2021 at 7:15 p.m. (CET)

]]>
Wed, 24 Feb 2021 17:15 GMT 2181731 en GlobeNewswire Inc. BBS-Bioactive Bone Substitutes Oyj Wed, 24 Feb 2021 17:15 GMT Company Announcement European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181731/0/fi/BBS-Bioactive-Bone-Substitutes-Oyj-Tilinp%C3%A4%C3%A4t%C3%B6stiedote-1-1-2020-31-12-2020-Tilintarkastamaton.html http://www.yebxqs.cn/news-release/2021/02/24/2181731/0/fi/BBS-Bioactive-Bone-Substitutes-Oyj-Tilinp%C3%A4%C3%A4t%C3%B6stiedote-1-1-2020-31-12-2020-Tilintarkastamaton.html Helsinki:BONEH Stockholm:BONEH FI4000260583 8877 BBS-Bioactive Bone Substitutes Oyj: Tilinp??t?stiedote 1.1.2020 - 31.12.2020 (Tilintarkastamaton) BBS-Bioactive Bone Substitutes Oyj: Tilinp??t?stiedote 1.1.2020 - 31.12.2020 (Tilintarkastamaton)

]]>
Wed, 24 Feb 2021 17:15 GMT 2181731 fi GlobeNewswire Inc. BBS-Bioactive Bone Substitutes Oyj Wed, 24 Feb 2021 17:15 GMT Company Announcement European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181728/0/en/Dr-Manola-cosmetic-surgery-procedures-increased-during-pandemic.html http://www.yebxqs.cn/news-release/2021/02/24/2181728/0/en/Dr-Manola-cosmetic-surgery-procedures-increased-during-pandemic.html Dr Manola: cosmetic surgery procedures increased during pandemic Self-care while wearing face masks]]> Wed, 24 Feb 2021 17:10 GMT 2181728 en GlobeNewswire Inc. Dott. Mirko Manola Wed, 24 Feb 2021 17:10 GMT Manola


]]>
GlobeNewswire Inc.
Research Analysis and Reports cosmetic surgery italy Milan Beauty
http://www.yebxqs.cn/news-release/2021/02/24/2181696/0/en/RAMSAY-SANTE-Half-year-Results-at-the-end-of-December-2020.html http://www.yebxqs.cn/news-release/2021/02/24/2181696/0/en/RAMSAY-SANTE-Half-year-Results-at-the-end-of-December-2020.html Paris:GDS FR0000044471 RAMSAY SANTE : Half-year Results at the end of December 2020 ???????????

]]>
Wed, 24 Feb 2021 16:35 GMT 2181696 en GlobeNewswire Inc. RAMSAY SANTE Wed, 24 Feb 2021 16:35 GMT Press releases Earnings Releases and Operating Results European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181696/0/fr/RAMSAY-SANTE-r%C3%A9sultats-semestriels-%C3%A0-fin-d%C3%A9cembre-2020.html http://www.yebxqs.cn/news-release/2021/02/24/2181696/0/fr/RAMSAY-SANTE-r%C3%A9sultats-semestriels-%C3%A0-fin-d%C3%A9cembre-2020.html Paris:GDS FR0000044471 RAMSAY SANTE : résultats semestriels à fin décembre 2020 COMMUNIQUé DE PRESSE
Paris, le 24 février 2021

]]>
Wed, 24 Feb 2021 16:35 GMT 2181696 fr GlobeNewswire Inc. RAMSAY SANTE Wed, 24 Feb 2021 16:35 GMT Press releases Earnings Releases and Operating Results European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181687/0/en/LIDDS-files-patent-application-for-method-to-treat-brain-cancer-with-intratumoral-depot-injections.html http://www.yebxqs.cn/news-release/2021/02/24/2181687/0/en/LIDDS-files-patent-application-for-method-to-treat-brain-cancer-with-intratumoral-depot-injections.html Stockholm:LIDDS SE0001958612 MyWeb LIDDS files patent application for method to treat brain cancer with intratumoral depot injections UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid? for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site.

]]>
Wed, 24 Feb 2021 16:19 GMT 2181687 en GlobeNewswire Inc. LIDDS AB Wed, 24 Feb 2021 16:20 GMT Company Announcement
http://www.yebxqs.cn/news-release/2021/02/24/2181664/0/en/Report-on-transactions-with-ALK-Abell%C3%B3-A-S-B-shares-and-associated-securities-by-managerial-staff.html http://www.yebxqs.cn/news-release/2021/02/24/2181664/0/en/Report-on-transactions-with-ALK-Abell%C3%B3-A-S-B-shares-and-associated-securities-by-managerial-staff.html Copenhagen:ALK B LSE:0OIR DK0060027142 Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions:

]]>
Wed, 24 Feb 2021 16:01 GMT 2181664 en GlobeNewswire Inc. ALK Abello Wed, 24 Feb 2021 16:01 GMT Insider's Buy/Sell European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181664/0/da/Indberetning-af-ledelsens-transaktioner-med-ALK-Abell%C3%B3-A-S-B-aktier-og-tilknyttede-v%C3%A6rdipapirer.html http://www.yebxqs.cn/news-release/2021/02/24/2181664/0/da/Indberetning-af-ledelsens-transaktioner-med-ALK-Abell%C3%B3-A-S-B-aktier-og-tilknyttede-v%C3%A6rdipapirer.html Copenhagen:ALK B LSE:0OIR DK0060027142 Indberetning af ledelsens transaktioner med ALK-Abelló A/S'?B-aktier og tilknyttede v?rdipapirer ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indberetter hermed f?lgende transaktioner:

]]>
Wed, 24 Feb 2021 16:01 GMT 2181664 da GlobeNewswire Inc. ALK Abello Wed, 24 Feb 2021 16:01 GMT Insider's Buy/Sell European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/24/2181635/0/zh-hans/Cybrexa-Therapeutics%E4%B8%8E%E7%BE%8E%E5%9B%BD%E5%9B%BD%E5%AE%B6%E7%99%8C%E7%97%87%E7%A0%94%E7%A9%B6%E6%89%80%E7%AD%BE%E8%AE%A2%E5%90%88%E4%BD%9C%E7%A0%94%E5%8F%91%E5%8D%8F%E8%AE%AE-CRADA-%E4%BB%A5%E5%BC%80%E5%8F%91CBX-12-alphalex-exatecan.html http://www.yebxqs.cn/news-release/2021/02/24/2181635/0/zh-hans/Cybrexa-Therapeutics%E4%B8%8E%E7%BE%8E%E5%9B%BD%E5%9B%BD%E5%AE%B6%E7%99%8C%E7%97%87%E7%A0%94%E7%A9%B6%E6%89%80%E7%AD%BE%E8%AE%A2%E5%90%88%E4%BD%9C%E7%A0%94%E5%8F%91%E5%8D%8F%E8%AE%AE-CRADA-%E4%BB%A5%E5%BC%80%E5%8F%91CBX-12-alphalex-exatecan.html Cybrexa Therapeutics与美国国家癌症研究所签订合作研发协议(CRADA)以开发CBX-12(alphalex?- exatecan) - Cybrexa与NCI将合作开发Cybrexa的主要候选药物CBX-12,以评估对实体肿瘤患者的安全性和疗效 -

]]>
Wed, 24 Feb 2021 15:38 GMT 2181635 zh-Hans GlobeNewswire Inc. Cybrexa Therapeutics Wed, 24 Feb 2021 15:38 GMT Health
http://www.yebxqs.cn/news-release/2021/02/24/2181618/0/en/Allarity-Therapeutics-Provides-Update-on-Pre-Clinical-Testing-of-Stenoparib-s-Antiviral-Activity-Against-New-Variants-of-Coronavirus.html http://www.yebxqs.cn/news-release/2021/02/24/2181618/0/en/Allarity-Therapeutics-Provides-Update-on-Pre-Clinical-Testing-of-Stenoparib-s-Antiviral-Activity-Against-New-Variants-of-Coronavirus.html Stockholm:ALLR DK0060732477 MyWeb Reg Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus Press Release ????

]]>
Wed, 24 Feb 2021 15:19 GMT 2181618 en GlobeNewswire Inc. Allarity Therapeutics A/S Wed, 24 Feb 2021 15:20 GMT Company Announcement European Regulatory News covid-19 SARS-Cov-2
http://www.yebxqs.cn/news-release/2021/02/24/2181587/0/en/Pan-Biome-Pharmaceuticals-Inc-reports-positive-results-in-preclinical-trial-of-Inflammatory-Bowel-Disease-oral-drug-shows-strong-effect-in-modulating-the-gut-microbiome.html http://www.yebxqs.cn/news-release/2021/02/24/2181587/0/en/Pan-Biome-Pharmaceuticals-Inc-reports-positive-results-in-preclinical-trial-of-Inflammatory-Bowel-Disease-oral-drug-shows-strong-effect-in-modulating-the-gut-microbiome.html Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical?company focused on?chronic inflammatory?and autoimmune diseases,?is pleased to announce that?one of its drugs?produced?strong effects?in modulating gut microbiota?in a mouse model study of?inflammatory bowel disease.?In a study run by the?Gut4Health Microbiome Core?at?BC’s Children’s Hospital Research Institute,?the?compound?induced?a?distinct?shift in?microbiota composition, by increasing?“good” bacteria?while?suppressing?bacteria?associated with?the development?of?obesity?and?type 2?diabetes.?Particularly exciting was the finding that our compound induced a substantial increase in the species Akkermansia?muciniphila, a bacterium?shown to elicit?a wide range of?positive health benefits,?including reduced?obesity and systemic inflammation, and improved?gut barrier function.?Chronic?diseases driven by?obesity and?obesity-related?conditions?accounted for?over?$480 billion?USD?in direct health care costs?in the U.S.?alone?(2016).?

]]>
Wed, 24 Feb 2021 15:00 GMT 2181587 en GlobeNewswire Inc. Pan-Biome Pharmaceuticals, Inc Wed, 24 Feb 2021 15:00 GMT Health autoimmune microbiome gut antioxidant microbiota modulation akkermansia disease probiotics diabetes obesity IBD chronic inflammation
http://www.yebxqs.cn/news-release/2021/02/24/2181599/0/en/22nd-Century-Group-Provides-Business-Update-Letter-from-CEO.html http://www.yebxqs.cn/news-release/2021/02/24/2181599/0/en/22nd-Century-Group-Provides-Business-Update-Letter-from-CEO.html NYSE: XXII US90137F1030 22nd Century Group Provides Business Update Letter from CEO Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis]]> Wed, 24 Feb 2021 15:00 GMT 2181599 en GlobeNewswire Inc. 22nd Century Group, Inc Wed, 24 Feb 2021 15:00 GMT Company Announcement http://www.yebxqs.cn/news-release/2021/02/24/2181572/0/en/Lixte-Biotechnology-to-Present-Its-Anti-Cancer-Therapy-Enhancer-LB-100-at-the-Virtual-H-C-Wainwright-Global-Life-Sciences-Conference.html http://www.yebxqs.cn/news-release/2021/02/24/2181572/0/en/Lixte-Biotechnology-to-Present-Its-Anti-Cancer-Therapy-Enhancer-LB-100-at-the-Virtual-H-C-Wainwright-Global-Life-Sciences-Conference.html Nasdaq:LIXT US5393191037 Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference EAST SETAUKET, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021.?Investors may register and consult the conference agenda at the event website.

]]>
Wed, 24 Feb 2021 14:35 GMT 2181572 en GlobeNewswire Inc. Lixte Biotechnology Holdings, Inc. Wed, 24 Feb 2021 14:35 GMT Press releases Lixte Biotechnology Holdings LIXT clinical-stage drug discovery drugs Anti-Cancer Therapy Enhancer LB-100 pharmaceutical PP2A
http://www.yebxqs.cn/news-release/2021/02/24/2181543/0/en/AIM-ImmunoTech-s-Subsidiary-Receives-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-Ampligen-to-Treat-Pancreatic-Cancer.html http://www.yebxqs.cn/news-release/2021/02/24/2181543/0/en/AIM-ImmunoTech-s-Subsidiary-Receives-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-Ampligen-to-Treat-Pancreatic-Cancer.html NYSE:AIM US00901B1052 AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.

]]>
Wed, 24 Feb 2021 14:15 GMT 2181543 en GlobeNewswire Inc. AIM ImmunoTech Inc. Wed, 24 Feb 2021 14:15 GMT Prof. Casper van Eijck, surgeon and a global leading expert in pancreatic cancer


]]>
GlobeNewswire Inc.
Kazem Kazempour, Ph.D., CEO and President of Amarex Clinical Research, LLC


]]>
GlobeNewswire Inc.
Health Product / Services Announcement pancreatic cancer
http://www.yebxqs.cn/news-release/2021/02/24/2181547/0/en/Generex-and-NuGenerex-Immuno-Oncology-Provide-Update-on-Ii-Key-COVID-19-Complete-Vaccine-Development-Program.html http://www.yebxqs.cn/news-release/2021/02/24/2181547/0/en/Generex-and-NuGenerex-Immuno-Oncology-Provide-Update-on-Ii-Key-COVID-19-Complete-Vaccine-Development-Program.html Other OTC:GNBT US3714853013 Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine? Development Program MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)? (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele, which is one of hundreds of alleles in the human immune system. HLAs?are proteins - or markers -found on most cells in your body. Your immune system uses these markers to recognize which cells belong in your body and which do not. So, for example, HLA is used to match patients and donors for bone marrow or organ transplants. The Ii-Key is specific for human HLA, so therefore does not work in other species, making it difficult to evaluate vaccine efficacy in animal models. The DR4 transgenic mouse provides an opportunity to evaluate the ability of Ii-Key vaccines to generate immune responses in an animal model, recognizing that the DR4 allele is only one of dozens of human HLA epitopes contained in the Ii-Key-SARS-CoV-2 vaccine.

]]>
Wed, 24 Feb 2021 14:15 GMT 2181547 en GlobeNewswire Inc. Generex Biotechnology Corporation Wed, 24 Feb 2021 14:15 GMT Company Announcement
http://www.yebxqs.cn/news-release/2021/02/24/2181503/0/en/CoImmune-Inc-Announces-Appointment-of-Ed-Baracchini-to-Board-of-Directors.html http://www.yebxqs.cn/news-release/2021/02/24/2181503/0/en/CoImmune-Inc-Announces-Appointment-of-Ed-Baracchini-to-Board-of-Directors.html CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors.

]]>
Wed, 24 Feb 2021 14:00 GMT 2181503 en GlobeNewswire Inc. CoIMMUNE Wed, 24 Feb 2021 14:00 GMT Directors and Officers
http://www.yebxqs.cn/news-release/2021/02/24/2181504/0/en/Locus-Biosciences-completes-first-of-its-kind-controlled-clinical-trial-for-CRISPR-enhanced-bacteriophage-therapy.html http://www.yebxqs.cn/news-release/2021/02/24/2181504/0/en/Locus-Biosciences-completes-first-of-its-kind-controlled-clinical-trial-for-CRISPR-enhanced-bacteriophage-therapy.html Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy Phase 1b trial demonstrates that the company’s lead precision medicine asset is safe and well tolerated]]> Wed, 24 Feb 2021 14:00 GMT 2181504 en GlobeNewswire Inc. Locus Biosciences Wed, 24 Feb 2021 14:00 GMT Health Product / Services Announcement locus biosciences http://www.yebxqs.cn/news-release/2021/02/24/2181513/0/en/Medexus-Schedules-Third-Quarter-Fiscal-2021-Conference-Call.html http://www.yebxqs.cn/news-release/2021/02/24/2181513/0/en/Medexus-Schedules-Third-Quarter-Fiscal-2021-Conference-Call.html TSX-V:MDP Other OTC:MEDXF Frankfurt:P731 CA58410Q2036 Medexus Schedules Third Quarter Fiscal 2021 Conference Call TORONTO and CHICAGO and MONTREAL, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)?today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along with its MD&A post market on March 1, 2021.

]]>
Wed, 24 Feb 2021 14:00 GMT 2181513 en GlobeNewswire Inc. Medexus Pharmaceuticals Inc Wed, 24 Feb 2021 14:01 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/02/24/2181516/0/en/Nass-Valley-Gateway-Ltd-NVG-Announces-It-Has-Retained-Former-Kannaway-CEO-Jeff-Rogers-as-Consultant.html http://www.yebxqs.cn/news-release/2021/02/24/2181516/0/en/Nass-Valley-Gateway-Ltd-NVG-Announces-It-Has-Retained-Former-Kannaway-CEO-Jeff-Rogers-as-Consultant.html Other OTC:NSVGF OTC Markets:NSVGF CNSX:NVG.CN Frankfurt:3NVN CA6315202029 Nass Valley Gateway Ltd (NVG) Announces It Has Retained Former Kannaway CEO Jeff Rogers as Consultant ?ROGERS WILL DESIGN AND LEAD THE ROLLOUT OF NVG’s PROPRIETARY “NASS VALLEY DIRECT” SALES CHANNEL

]]>
Wed, 24 Feb 2021 14:00 GMT 2181516 en GlobeNewswire Inc. Nass Valley Gateway Ltd Wed, 24 Feb 2021 14:01 GMT Press releases
http://www.yebxqs.cn/news-release/2021/02/24/2181525/0/en/Syneos-Health-and-Protocol-First-Partner-to-Accelerate-Collection-and-Review-of-Clinical-Trial-Data.html http://www.yebxqs.cn/news-release/2021/02/24/2181525/0/en/Syneos-Health-and-Protocol-First-Partner-to-Accelerate-Collection-and-Review-of-Clinical-Trial-Data.html Nasdaq:SYNH US45329R1095 Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review]]> Wed, 24 Feb 2021 14:00 GMT 2181525 en GlobeNewswire Inc. Syneos Health, Inc. Wed, 24 Feb 2021 14:01 GMT Partnerships clinical trials Clinical Trial Data Electronic Health Records Electronic Data Capture Dynamic Assembly Software
粉色午夜视频/色戒未删减版在线观看视频/44383x3全国最大的免费观看/冲田杏梨番号